|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
JP2005508838A
(ja)
*
|
2001-03-23 |
2005-04-07 |
アフトン コーポレーション |
膵癌の組合せ治療
|
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
|
AU2002326356A1
(en)
*
|
2001-07-09 |
2003-01-29 |
Aphton Corporation |
Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
|
|
US20060165675A1
(en)
*
|
2002-08-02 |
2006-07-27 |
Richman-Eisenstat Janice Beth |
Modulation of mesenchymal cells via iga-receptors
|
|
WO2004088326A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Aphton Corporation |
Gastrin hormone immunoassays
|
|
US20060020119A1
(en)
*
|
2004-03-29 |
2006-01-26 |
Stephen Grimes |
Monoclonal antibodies to gastrin hormone
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP1570858A1
(en)
*
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
|
|
EP1794586B1
(en)
|
2004-09-22 |
2013-01-30 |
Cancer Advances, Inc., |
Monoclonal antibodies to progastrin
|
|
ES2417065T3
(es)
|
2005-04-26 |
2013-08-05 |
Trion Pharma Gmbh |
Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
|
|
EP2295080A3
(en)
|
2005-07-25 |
2011-06-22 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
AU2008289857B2
(en)
|
2007-08-23 |
2014-06-05 |
Phc Corporation |
Use of non-specific reaction inhibitor
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
EP2127666A1
(en)
*
|
2008-05-28 |
2009-12-02 |
Drug Discovery Factory B.V. |
Method for the treatment or prophylaxis of chronic inflammatory diseases
|
|
WO2011088219A2
(en)
*
|
2010-01-13 |
2011-07-21 |
The Uab Research Foundation |
Therapeutics and processes for treatment of immune disorders
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
JP6017422B2
(ja)
|
2010-08-10 |
2016-11-02 |
エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） |
赤血球結合療法
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2465536A1
(en)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89 activation in therapy
|
|
CN108324943B
(zh)
*
|
2012-02-10 |
2024-03-08 |
思进股份有限公司 |
Cd30+癌症的检测和治疗
|
|
EP2636681A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Process for enriching IgA
|
|
EP2636684A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Prevention of infection
|
|
MX360245B
(es)
|
2012-03-09 |
2018-10-26 |
Csl Behring Ag |
Composiciones que comprenden inmunoglobulinas de tipo secretor.
|
|
KR20240154672A
(ko)
|
2014-02-21 |
2024-10-25 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
글리코타겟팅 치료제
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
CN107428840A
(zh)
*
|
2015-03-25 |
2017-12-01 |
弗劳恩霍夫应用研究促进协会 |
抗cd89细胞毒素的复合物
|
|
UY36751A
(es)
|
2015-06-26 |
2017-01-31 |
Novartis Ag |
Anticuerpos de factor xi y métodos de uso
|
|
KR102784293B1
(ko)
|
2015-09-21 |
2025-03-20 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
CA3037694C
(fr)
*
|
2016-09-30 |
2023-11-14 |
Centre National De La Recherche Scientifique |
Marqueurs cellulaires
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
EP3551034A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
BR112019012667A2
(pt)
|
2016-12-23 |
2020-02-11 |
Novartis Ag |
Anticorpos do fator xi e métodos de uso
|
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
KR102772810B1
(ko)
|
2017-06-15 |
2025-02-28 |
캔서 어드밴시스 아이엔씨 |
종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
|
|
EP3638296A1
(en)
|
2017-06-16 |
2020-04-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
SG11202011078VA
(en)
|
2018-05-09 |
2020-12-30 |
Univ Chicago |
Compositions and methods concerning immune tolerance
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
WO2020106757A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
CN121197633A
(zh)
|
2019-12-13 |
2025-12-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
KR20230004739A
(ko)
*
|
2020-04-21 |
2023-01-06 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
인간화 항-인간 cd89 항체 및 이의 용도
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022098084A1
(ko)
*
|
2020-11-06 |
2022-05-12 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
KR102855679B1
(ko)
*
|
2020-11-06 |
2025-09-04 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
KR102766045B1
(ko)
*
|
2020-11-06 |
2025-02-10 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 향상된 항체
|
|
KR102853685B1
(ko)
*
|
2020-11-06 |
2025-09-01 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 증진된 항체
|
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
|
EP4698563A1
(en)
|
2023-04-19 |
2026-02-25 |
Centessa Pharmaceuticals (UK) Limited |
Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
|
|
CN117890576A
(zh)
*
|
2023-12-12 |
2024-04-16 |
深圳市陆为生物技术有限公司 |
一种检测CD89-IgA免疫复合物的试剂、方法及其应用
|
|
WO2025218725A1
(zh)
*
|
2024-04-18 |
2025-10-23 |
徕特康(苏州)生物制药有限公司 |
靶向cd20和cd89的髓细胞衔接子抗体及其用途
|
|
WO2026002175A1
(zh)
*
|
2024-06-27 |
2026-01-02 |
无锡徕特康生物科技有限公司 |
靶向ilt7和cd89的髓细胞衔接子抗体及其用途
|